Biodexa Pharmaceuticals (BDRX) announced the results of its Type C meeting with the U.S. Food and Drug Administration, FDA, regarding the ...
20hon MSN
The US Food and Drug Administration on Thursday issued recommendations for the composition of influenza shots for the ...
Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAPClears the way to ...
The recommendations were made in a closed session with representatives from CBER, the CDC and Department of Defense.
Encelto is the first FDA-approved treatment for macular telangiectasia type 2. The cell therapy slows the loss of macular photoreceptors through continuous delivery of ciliary neurotrophic factor.
But beware. Health and Human Services Secretary Robert F. Kennedy, Jr. has called for “conflict-free” advisory committee ...
Tandem Diabetes Care has secured a new FDA clearance for its insulin dose-calculating algorithm, opening up its use to adults with Type 2 diabetes ... for Diabetes meeting scheduled for next ...
Novo Nordisk’s Ozempic and Lilly’s Mounjaro treat Type 2 diabetes ... of the only real, FDA-approved semaglutide medicines is resolved, affirming that Novo Nordisk is meeting or exceeding ...
ALPHARETTA, Ga., March 06, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company ...
Revakinagene taroretcel-lwey (Encelto; Neurotech), an allogeneic encapsulated cell-based gene therapy, is the first therapy to be approved for macular telangiectasia type 2. The FDA approved ...
Encelto, the first FDA-approved treatment for MacTel, is implanted intravitreally during a surgery performed by a qualified ophthalmologist. The Food and Drug Administration (FDA) has approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results